What it is
Tirzepatide is a dual GIP and GLP-1 receptor agonist registered as a prescription medicine in a number of jurisdictions for defined indications.
The Range
TR10 · Pen · Metabolic research
Tirzepatide 5 mg pen
Approved medicineEvidence: Established
A dual GIP/GLP-1 receptor agonist approved in several markets as a prescription medicine. Only registered, prescribed product from licensed channels should ever be considered.
Evidence highlights
Mechanism being studied
Agonism at GIP and GLP-1 receptors influences insulin secretion, gastric emptying and appetite regulation.
Human evidence
Large randomised controlled trials underpin its approved indications. Evidence applies to the registered product used under prescription, not to unregistered copies.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.